Table 2.

Number need to harm (NNH) to each adverse event assessed in the meta-analysis.

	Rimonabant treated	Event	Placebo treated	Event	CER (%)	EER (%)	NNH
Any adverse event
Rimonabant 5 mg	2883	2364	1770	1434	81	82	102
Rimonabant 20 mg	3393	2861	2292	1829	80	84	22
Total	6276	5225	4062	3263	80	83	34
Serious adverse events
Rimonabant 5 mg	2883	149	1770	79	4	5	142
Rimonabant 20 mg	3393	207	2292	123	5	6	136
Total	6276	356	4062	202	5	6	143
Discontinuation due to adverse events
Rimonabant 5 mg	2883	232	1770	125	7	8	102
Rimonabant 20 mg	3815	501	2708	206	8	13	18
Total	6698	733	4478	331	7	11	28
Discontinuation due to psychiatric adverse events
Rimonabant 5 mg	2883	81	1770	42	2	3	229
Rimonabant 20 mg	3815	230	2708	72	3	6	30
Total	6698	311	4478	114	3	5	48
Discontinuation due to neurologic adverse events
Rimonabant 5 mg	2883	26	1770	13	1	1	597
Rimonabant 20 mg	3684	78	2581	25	1	2	87
Total	6567	104	4351	38	1	2	141

CER, control event rate; EER, experimental event rate.